EyePoint (EYPT) Deferred Taxes (2011 - 2025)
EyePoint (EYPT) posted Deferred Taxes of $369000.0 for Q4 2025, up 310.0% sequentially from $90000.0 in Q4 2024, and up 310.0% YoY from $90000.0 in Q4 2024.
Powered by 
Analysis
EyePoint (EYPT) Deferred Taxes (2011 - 2025) Analysis & Trends
EyePoint has reported Deferred Taxes for 3 years, with the latest figure at $369000.0 in Q4 2025.
- Quarterly Deferred Taxes rose 310.0% year-over-year to $369000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $459000.0 (up 410.0% YoY) and the FY2025 annual result came in at $279000.0, up 210.0% from the prior year.
- Deferred Taxes grew to $369000.0 in Q4 2025 per EYPT's latest filing, from $90000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $369000.0 in Q4 2025 and troughed at $90000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Sep 30, 2011 | -13,000.00 |
| Jun 30, 2011 | -119,000.00 |